Trametinib (Mekinist; Spexotras oral solution)

Medicine at a glance

Trametinib is a targeted cancer medicine taken once daily. Mekinist is a verified brand; Spexotras is a verified trametinib oral-solution product used in specialist children's treatment. The medicine blocks proteins called MEK1 and MEK2, which carry growth signals inside cells. It may be prescribed alone or with dabrafenib, which blocks another part of this signalling pathway.

The tablet and liquid instructions are different. Your dose, food timing and storage instructions must match the product you receive. Important risks include weakened heart pumping, eye problems, lung inflammation, bleeding and severe skin reactions. Fever needs particular attention with dabrafenib.

This guide supports your discussions with the treating team. Your prescription and supplied product leaflet take priority for your individual treatment. For children, a trained caregiver should know the exact dose and urgent-help plan.

What trametinib is and how it works

Cells use linked proteins to relay messages telling them when to grow. A change in the BRAF gene can make this pathway overactive. Trametinib blocks MEK proteins further along the pathway; dabrafenib acts on altered BRAF. Combining them can block the pathway at two points when that is appropriate for the cancer.

Trametinib is a small-molecule targeted treatment, not conventional chemotherapy or an immune-checkpoint medicine. Targeted treatment can still affect healthy tissues and cause serious side effects. A biomarker result helps the team select treatment but does not guarantee that it will work.

Some treatment plans continue while the medicine is helping and side effects remain manageable. Others have a planned end date. Ask what the goal is in your own situation and how scans, examinations and symptoms will be used to judge progress. Do not continue beyond, or stop before, the prescribed course without advice.

How the team decides whether it is suitable

The oncologist considers your diagnosis, previous treatment, general health and applicable prescribing information. In the labelled treatment settings, testing confirms an appropriate BRAF change, such as V600E or V600K depending on the situation. The precise variant and clinical context matter; a report simply saying “BRAF positive” is not enough to interpret by yourself.

Age and formulation also matter. Current US information supports selected combination treatment from one year of age, but not trametinib alone in children. US paediatric tablet dosing starts at a body weight of 26 kg. European Mekinist tablets include selected adolescent use from age 12; Spexotras liquid is used in selected children from age one. These are not permissions to substitute products or extend treatment to every child.

Tell the team about heart disease, high blood pressure, diabetes, eye disease or a previous retinal vein blockage, breathing problems, bleeding, clots, bowel inflammation, and liver or kidney disease. Severe kidney disease and moderate or severe liver impairment require specialist assessment. US labelling does not establish a recommended dose for moderate or severe liver impairment; European information advises caution.

Before treatment starts

Bring all medicines, supplements and herbal products, including anything bought without a prescription. Do not use trametinib if you have a known allergy to it or an ingredient. Tell the team about other allergies, pregnancy possibility, breastfeeding, previous radiotherapy and any planned operations or dental procedures. If dabrafenib is prescribed, mention known G6PD deficiency, an inherited condition that can make red blood cells vulnerable to breakdown.

You will usually have blood counts and tests of liver function, kidneys and blood salts. Blood glucose is particularly relevant if you have diabetes. Blood pressure and heart pumping function are checked before treatment. Tell the team about existing vision changes so that appropriate eye assessment can be arranged. A pregnancy test is required by US guidance when pregnancy is possible.

For the liquid, ask the pharmacist to demonstrate preparation of each measured dose, storage, syringe cleaning and any feeding-tube method. For a child, confirm how weight changes will trigger a prescription review. Leave with the hospital's urgent contact arrangements, a fever plan and enough information to manage missed or vomited doses.

How to take trametinib

Daily dose and food timing

A usual adult tablet dose is 2 mg once daily, about 24 hours apart. This is an example, not your personal instruction. Tablets come in 0.5 mg and 2 mg strengths. A treatment pause or lower dose may be needed for side effects. Children and people using liquid have weight-based dosing; do not calculate a child's dose from an adult example.

Take tablets on an empty stomach, at least one hour before or two hours after a meal, with water. Swallow whole; do not chew, crush or break them. When dabrafenib is also prescribed, trametinib is usually taken with either its morning or evening dose, consistently each day. The partner still has its own twice-daily schedule.

US Mekinist oral solution used alone may be taken with a low-fat meal or on an empty stomach. With dabrafenib, the liquid must be taken on an empty stomach. Spexotras is prescribed with dabrafenib dispersible tablets and follows the same fasting interval. For a young child unable to tolerate fasting, the liquid-product instructions allow breastfeeding or formula on demand; agree the feeding plan with the team.

Using the oral solution safely

Mekinist oral solution and Spexotras are prepared by the pharmacist to a concentration of 0.05 mg/mL. You should receive a ready-mixed solution. Do not mix a bottle of powder yourself or add water to the finished bottle. If the wrong form arrives, contact the pharmacy before giving it.

Check the prescribed volume in millilitres and the discard date. Gently swirl the bottle for 30 seconds and allow foam to settle before measuring. Use the supplied oral syringe, not a kitchen spoon. Give the medicine slowly towards the inside of the cheek, with the child upright, to reduce choking risk. Wash and dry the syringe as demonstrated and use a new syringe with each new bottle.

A pharmacy-supervised feeding-tube method is available. US and European patient instructions specify an NG or gastric tube of at least 4 French. Confirm the exact tube, syringe connection and flushing plan. Do not crush tablets into a tube as a substitute. Dose volumes differ across weight bands, so changing between tablets and solution needs a new prescription check.

Missed doses, vomiting and storage

Take a forgotten trametinib dose only when more than 12 hours remain before the next scheduled dose; otherwise skip it. Never double a dose. Dabrafenib has a different missed-dose interval, so check its separate instructions. If vomiting occurs after trametinib, do not repeat the dose; take the next at its usual time. Report repeated vomiting or an accidental extra dose promptly.

Storage differs by product and region. Current US tablets are stored at 20–25°C (68–77°F), with permitted short excursions to 15–30°C (59–86°F), in the original bottle with its moisture-absorbing insert. Do not transfer them to a pill box. Current European tablets require original packaging; after opening, keep at no more than 30°C (86°F) and use within 30 days. Follow your supplied label rather than older advice that all trametinib tablets need refrigeration.

Prepared liquid is kept below 25°C (77°F), upright in its original bottle and carton, and must not be frozen. Discard it 35 days after pharmacy preparation, using the date on the bottle. The unmixed powder's refrigerated storage is a pharmacy instruction, not the storage rule for your prepared liquid. Keep all forms away from children and pets. Ask the pharmacy how to dispose of unused treatment safely.

Monitoring and checking whether treatment is working

Heart pumping is measured before treatment, after about one month and then regularly. US guidance specifies every two to three months thereafter; European guidance approximately every three months. These scans can detect a change before symptoms appear. Blood pressure is also checked during treatment.

European information recommends liver tests every four weeks for the first six months, with further testing as needed. Blood counts, kidney function, salts and glucose are checked according to your plan and symptoms. Severe fever may need additional kidney tests. For children, weight and development are reviewed alongside treatment tolerability.

Current US information calls for periodic eye assessment and assessment whenever visual symptoms occur. Do not wait for a scheduled test if vision changes. With dabrafenib, the team also checks for new skin cancers before treatment, usually every two months during it and for up to six months afterwards.

Scans and clinical reviews assess the cancer separately from safety tests. Keep a record of doses, temperatures, bowel changes, skin symptoms and new medicines. A temporary pause may protect you from a serious complication; it does not automatically mean the treatment has failed.

Common side effects and practical management

Skin, nails and mouth

An acne-like rash, dry or itchy skin and inflammation around nails can occur. Use gentle cleansers and an unperfumed moisturiser. Avoid picking spots and damaging cuticles. Ask which creams are suitable; harsh acne products may irritate treatment-related rash. Report a painful, spreading or infected-looking area promptly. Reactions can also occur within existing tattoos; report new itching, swelling or soreness there.

A soft toothbrush and gentle mouth care can help sore gums or ulcers. Tell the team if mouth pain interferes with eating or drinking. Widespread blistering, peeling skin, mouth or eye sores, or rash with fever is different from a routine rash: withhold treatment and seek immediate assessment. Severe drug-related skin reactions require permanent discontinuation under specialist care.

Diarrhoea, nausea and appetite

Tell the team early about diarrhoea and use its prescribed management plan. Take frequent small drinks, unless your fluid allowance is restricted, and record how often loose stools occur. Fever, blood in the stool, severe pain, dizziness or reduced urine requires urgent contact rather than simply taking more anti-diarrhoea medicine.

Use prescribed anti-sickness treatment and try small, regular meals around the fasting schedule. Report persistent vomiting, falling weight or difficulty maintaining fluids. A dietitian can help balance nutrition with treatment timing, especially for a child.

Fatigue, aches, nerve symptoms and swelling

Balance rest with manageable activity. Anaemia, illness and treatment can all contribute to fatigue, so report a marked change. Ask before starting pain medicines. Muscle or joint aches can occur, but severe weakness or muscle pain with dark urine needs urgent assessment for muscle breakdown.

Report new numbness, tingling, burning pain or weakness, especially if it affects walking or hand movements. These nerve symptoms can persist and may need treatment changes.

Swelling around ankles or other areas can occur. New swelling, rapid weight gain or breathlessness may indicate a heart problem and needs prompt contact. Do not assume that all swelling is harmless fluid retention. Hair thinning or other hair changes are possible; the amount varies and complete hair loss is not inevitable.

Important risks that need medical assessment

Fever and severe inflammatory reactions

Fever is especially common with dabrafenib and can become serious through dehydration, low blood pressure or kidney injury. At 38°C (100.4°F) or above, withhold trametinib and both medicines if taking the combination, and contact your team immediately. Follow an earlier-contact threshold if your hospital has given one. Recurrent episodes may need interruption at the first warning symptoms under your written plan.

A fever may represent infection, a treatment reaction or another condition. Do not assume the cause or restart simply because paracetamol lowers the temperature. The team decides when to restart; US guidance requires recovery for at least 24 hours. Steroids or preventive fever medicines are sometimes prescribed, but should not be started from leftover supplies.

Rarely, the combination can trigger HLH, a severe overactivation of the immune system. Persistent fever with marked illness, unusual bruising, rash or abdominal swelling requires urgent assessment. Suspected HLH requires interruption while investigated, and confirmed HLH requires discontinuation and specialist treatment.

Heart, blood pressure and clots

Trametinib can weaken the heart's pumping action. Contact the team for new breathlessness, difficulty lying flat, swollen ankles, rapid weight gain or palpitations. Chest pain, fainting or severe breathlessness is an emergency. Inflammation of the heart muscle and abnormal heart rhythms are also reported. High blood pressure may have no symptoms, which is why measurements matter.

A clot can cause a swollen, painful arm or leg, or sudden chest pain and breathlessness if it travels to the lungs. Seek immediate medical care. The team may withhold, reduce or permanently stop treatment depending on severity; never treat a suspected clot at home.

Eyes and lungs

Blurred vision, reduced central vision, flashing lights, eye pain or other new visual symptoms need immediate contact. The US label calls for eye assessment within 24 hours for reported visual disturbance. A blocked retinal vein requires permanent trametinib discontinuation. Fluid under the retina has a different management plan and may sometimes allow a supervised restart. Sudden loss of vision is an emergency.

New cough, breathlessness or fever can indicate lung inflammation, infection or another serious problem. Withhold trametinib and obtain immediate advice before another dose when these symptoms develop. The team investigates suspected treatment-related lung inflammation and permanently stops it if confirmed. Do not self-diagnose or wait for the next scan.

Sarcoidosis, an inflammatory condition affecting organs such as the lungs, skin and eyes, is also reported with the combination. New cough, swollen glands or tender skin lumps need assessment; they do not by themselves prove cancer progression.

Bleeding, bowel and other organ problems

Report unusual bruising or bleeding promptly. Vomiting blood, black tar-like stools, heavy bleeding, or a sudden severe headache with weakness or confusion requires emergency care. Severe abdominal pain, particularly with fever, vomiting or a swollen abdomen, can indicate bowel inflammation, a tear in the bowel or pancreatic inflammation.

Yellow skin or eyes, dark urine or pale stools can indicate liver injury. Low blood counts can increase infection, anaemia or bleeding risk, particularly in children receiving the combination. Marked thirst or frequent urination may indicate high glucose, especially with dabrafenib. Combination treatment can rarely cause tumour lysis syndrome, when rapid cancer-cell breakdown disrupts blood salts and kidney function. High-risk patients may need additional tests and preventive hydration. Reduced urine, severe weakness, cramps or confusion needs urgent assessment.

With dabrafenib, report new skin lumps, non-healing sores or changing moles. Rare new cancers can occur and surveillance continues after treatment. Tell the team about radiotherapy before, during or after treatment: the combination can intensify reactions in irradiated areas, occasionally affecting deeper tissues as well as skin. New weakness or altered bladder or bowel control after spinal radiotherapy is an emergency.

Other medicines, supplements and vaccines

Have the pharmacist check every new prescription, over-the-counter product and supplement. European guidance advises caution with strong inhibitors of the P-gp transport protein, including verapamil, ciclosporin, ritonavir and itraconazole. For certain medicines such as pitavastatin, the pharmacist may advise a two-hour separation. Do not apply that spacing rule to every medicine.

Spexotras contains an ingredient called sulfobutylbetadex that may affect absorption of some other oral medicines, particularly those where small blood-level changes matter. Mention drugs such as imipramine or desipramine. Dabrafenib adds further interactions, including effects on hormonal contraception, blood thinners and medicines processed by liver enzymes. A medicine safe with trametinib alone may need a different plan with the combination. Macmillan advises avoiding grapefruit and Seville oranges with the combination because of the dabrafenib interaction.

Ask the team about vaccines before arranging them. Live vaccines require individual advice based on your treatment and immune function; non-live vaccines may be offered at an appropriate time. Tell other doctors and dentists about cancer treatment before procedures, and do not stop prescribed medicines without a coordinated plan.

Everyday life during treatment

Plan meals around the actual formulation's instructions, and ask for nutritional support if this becomes difficult. Keep a thermometer and a clear fever plan at home. Carry the labelled medicine and prescription when travelling, maintaining the correct temperature and arranging blood tests and urgent-care access in advance.

Gentle activity, rest breaks and flexible work or school arrangements may help. Avoid driving or operating machinery if tired, dizzy or visually impaired. Use sun protection and report changing skin lesions. Check with the team about alcohol because liver problems and other medicines may affect what is appropriate.

Emotional strain, disrupted sleep and changes in intimacy deserve attention. Ask about counselling, practical assistance or age-appropriate support for a child. Discuss contraception openly even if fertility seems reduced. Tell the team when caregiving or dose measurement is becoming difficult so that support can be arranged.

Pregnancy, contraception, fertility and breastfeeding

Trametinib can harm an unborn baby. Discuss pregnancy testing and effective contraception before treatment, and contact the team promptly if pregnancy is suspected. US guidance requires effective contraception during treatment and for four months after the last dose; European guidance specifies at least 16 weeks. These are differently stated intervals, so ask for an actual end date.

US guidance also advises condoms for male patients with pregnant partners or partners who could become pregnant, including after vasectomy, during treatment and for four months afterwards. European trametinib information does not specify the same fixed male interval; the full combination plan must be checked. Dabrafenib can reduce hormonal contraception's effectiveness, requiring a suitable non-hormonal alternative or additional method. Do not shorten trametinib's precautions to the shorter US dabrafenib interval.

Do not breastfeed while taking trametinib. US guidance extends this restriction for four months after the last dose. European information does not give a fixed post-treatment restart interval; obtain individual advice. Permission for a child receiving liquid treatment to drink breast milk is a different issue from a mother breastfeeding while she herself takes trametinib.

Trametinib may impair fertility; dabrafenib can also impair sperm production, potentially permanently. Human long-term effects are not fully known. Discuss sperm, egg or other fertility-preservation options before treatment where relevant, including age-appropriate counselling for adolescents.

After a pause or when treatment finishes

Restart only when the team confirms which medicine, dose and schedule to use. Some side effects require both medicines to pause, while others affect only trametinib or dabrafenib. Do not assume that the partner automatically restarts at the same time.

Keep follow-up appointments and continue reporting new breathing, eye, heart or bleeding symptoms. Skin surveillance with dabrafenib may continue for six months. Maintain contraception and breastfeeding precautions for the specified period, return unwanted medicine safely, and clarify the next scan and ongoing support plan.

Frequently asked questions